Story perspectives

Eli Lilly Invests $2.75 Billion in AI Drug Collaboration

3/29/2026

Summary

Story summary

Eli Lilly and Company signed a $2.75 billion collaboration with Insilico Medicine to develop drugs using artificial intelligence.
Insilico Medicine will receive $115 million upfront, with additional payments tied to regulatory and commercial milestones.
Eli Lilly and Company will hold exclusive rights to develop and sell preclinical oral drug candidates for specific diseases.
Insilico Medicine has created 28 drugs with generative AI, with nearly half already in clinical stages.

1 of 1

Story summary

Eli Lilly and Company signed a $2.75 billion collaboration with Insilico Medicine to develop drugs using artificial intelligence.
Insilico Medicine will receive $115 million upfront, with additional payments tied to regulatory and commercial milestones.
Eli Lilly and Company will hold exclusive rights to develop and sell preclinical oral drug candidates for specific diseases.
Insilico Medicine has created 28 drugs with generative AI, with nearly half already in clinical stages.